Rabobank: Uncertainty for global beef markets
However, since US President Donald Trump took office in January 2025, uncertainty and unpredictability have reverberated through the global beef market.
With beef as one of the largest agricultural commodities traded by the US, any change to US trading arrangements has the potential to affect the beef market at a national and, in turn, a global level.
With the global supply and demand situation, RaboResearch expects trade flows to be maintained.
Source: RaboResearch
However, this is likely to change if major trading blocs such as Europe and China become involved in a trade war with the US.
Contracting supplies driving up cattle prices
Global cattle markets have been trending higher in the first half of 2025, according to RaboResearch.
European prices experienced an especially strong rise in the first quarter of 2025, as domestic supplies contracted while demand remained strong.
Senior analyst – Animal Protein for RaboResearch, Angus Gidley-Baird said: 'The rise in European prices now puts them in line with the strong North American cattle prices, which continue to rise slowly.
'In both Europe and the US, disease and pests are affecting cattle supplies. In Europe, and now in the UK, bluetongue continues to affect the herd.
'Meanwhile, New World screwworm in Mexico has caused US authorities to close the border to Mexican cattle imports, and the risk of potential infestation in the US is increasing.'
These health threats are challenging production in markets where cattle supplies are already historically low, likely further supporting already elevated cattle prices.
Production declines
Global beef production is expected to contract through the remainder of the year, with an overall contraction of 2% projected for the year, according to researchers at Rabobank.
The largest contractions are expected to happen in Brazil (down 5%) and New Zealand (down 4%), with contractions also expected in Europe, the US, and China.
Australia is one of the few regions expected to see a production increase.
Global trade managing disruptions
On April 5, tariffs were introduced for many countries exporting beef into the US.
Additional, so-called reciprocal tariffs for identified countries are on hold until early July, and the US-China tariff escalation has also been put on hold until early August.
While negotiations are ongoing, some redistribution of beef trade volumes around the world is becoming apparent.
Reports are emerging that Chinese buyers are looking more toward Australian, New Zealand, and South American suppliers as US beef becomes more expensive.
Global beef demand to remain stable
Although the full extent of the trade war remains uncertain, RaboResearch has stated that it remains cautiously optimistic about beef demand and trade flows.
'Beef isn't being singled out as a targeted commodity, and most major exporters are only facing baseline tariffs,' Gidley-Baird continued.
'So early indications suggest that competitive positions will be maintained, albeit with added costs to the system.
'The global supply and demand situation should maintain current trade flows. But if the US-China tariff war escalates and Europe becomes more involved, this is likely to change.
'Much of the media attention has been on the imposition of tariffs, but this may only be the opener to the main event,' he added.
However, RaboResearch said that while tariffs may have grabbed headlines, the real story will be the implications of shifting global trade dynamics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
2 hours ago
- Irish Examiner
Core US prices rise as tariffs impact costs
US prices continued to rise in July, according to key economic data released on Tuesday, as Donald Trump's international tariffs shake-up started to impact consumer costs. Prices were 2.7% higher last month compared with a year ago, according to the consumer price index (CPI), which measures the prices of a basket of goods and services. Though inflation dipped down in the spring, the annualised inflation rate jumped up 0.4% since April. Though the inflation rate stayed stable between June and July, core inflation, which excludes the volatile energy and food industries, went up 3.1% over the last month — a higher pace than what was seen in June. Prices for takeout and restaurants jumped up 3.9% over the last year, pushing up overall food prices by 2.9%. Prices for used cars, housing and medical care also jumped up higher than the overall rate. Overall, energy prices were down 1.6% for the year, what probably stabilised the overall pace of inflation. The report is the latest to show the US economy is experiencing some turbulence from Mr Trump's unparalleled shake-up of US trading policy, despite insistence from Republicans the economy is 'firing on all cylinders'. On top of a 10% universal tariff on all imports, Mr Trump has set higher tariffs for dozens of countries, including the US's top trading partners. On Monday, hours before a midnight deadline, Trump delayed enacting steep tariffs on China for another 90 days while negotiations continue. Although many of these tariffs only went into effect from August 7, Trump's 10% universal tariff, along with higher tariffs on certain industries like steel and aluminum, have been in effect since the spring. Economists say it takes time for tariffs to show up in consumer prices. Some retailers have been stocking up their inventory to delay the impact of tariffs and keep prices stable. But the jump in prices suggests companies have started to pass down costs to customers, as leaders of companies like Walmart, Nike and Macy's have said would happen. Tariffs have also hit the labour market harder than economists had anticipated. Data released earlier this month dramatically revised down job figures that initially showed a healthy job market. The government had reported 291,000 jobs were added to the economy in May and June, but the revision brought the total down to 33,000. The increase in prices and the shrinking labour market has thrown the US Federal Reserve into a tight spot. The Fed's twin mandate is to maximise employment while keeping inflation in check. Trump has lambasted the central bank, arguing it needs to cut rates interest rates in order to spur growth. But Fed officials have refrained from a rate adjustment, citing uncertainty about the impact of Trump's tariffs on prices. Trump has spent the last few months directing his ire at economic officials — first at the Fed, and now at the Bureau of Labor Statistics (BLS), which collects and reports economic data. Just hours after July's job figures report showed a sluggish month of job growth, Trump fired Erika McEntarfer, the commissioner of BLS. Citing no evidence, Trump claimed the job figures 'were RIGGED." On Wednesday, he nominated economist EJ Antoni, longtime critic of the BLS, to oversee the department. After the latest inflation figures were released, Trump claimed: 'It has been proven, that even at this late stage, tariffs have not caused inflation, or any other problems for America, other than massive amounts of CASH pouring into our Treasury's coffers.' The Guardian
The Journal
2 hours ago
- The Journal
The millionaire millennial seeking the presidency: How did Gareth Sheridan get so rich?
BUSINESSMAN GARETH SHERIDAN is seeking to become the youngest-ever Irish presidential candidate during this year's election, and claims to have secured support to make that possible. Much of the Irish public were introduced to 35-year-old Sheridan for the first time this week as a millionaire, pharmaceutical tycoon who recently returned to Ireland having spent the last seven years building up his company in the US. But how, exactly, did he earn his millions? And what does his company do? Acquisitions and mergers Nurtiband, a US-based healthcare-led company valued at approximately $80m, was started by Sheridan in 2012, during his final year at DIT in Dublin, where he was studying businesses and management. Taking inspiration from a transdermal patch his father had for a heart condition, Sheridan wrote his undergraduate thesis on providing properly-dosed medicine to patients through more accessible means, like patches, which are less likely to abuse. Early social media posts from Sheridan show that the company began by selling supplements, such as energy and metabolism-boosting patches, but the Dubliner wanted to branch out into the opioid market. Former Áras contender Seán Gallagher was later enlisted as the company's President (he has since left and has no current relationship with Sheridan) as the CEO worked towards getting the company listed on the Nasdaq stock exchange. Nutriband's strategy focused on carrying out a number of mergers and acquisitions, purchasing companies through its own stock options as a private company, over the last ten years, Sheridan explained on The Entrepreneur Experiment podcast in April. Sheridan focused on merging with firms with existing specialities in pharmaceuticals and biotechnology. It listed on the New York-based stock exchanged in October 2023, generating over $6m on its first day. Nutriband has now focused wholly on opioids through transdermal patches – similar to products used for nicotine-replacement therapy. Opioids, a type of pain-relief medication, have proven to be addictive among some patients. While they are an effective method to treat chronic pain, doctors – particularly in the US – have been reluctant to prescribe the medicines. Image posted by Sheridan in 2023 after his company was listed on the Nasdaq stock exchange in New York. Gareth Sheridan Gareth Sheridan As a result, more people have sought to purchase opioids illegally, and the black market drugs trade responded by introducing potent or synthetic alternatives over the last decade. The most-famous of these in the US is fentanyl, currently. Sheridan said that the most-important of Nutriband's acquisitions was the purchase of 4P Therapeutics in 2018, a company from two pharma veterans who created AVERSA technology , which prevents the misuse of opioids. It is today his lead product. During one acquisition, Nutriband pulled out of purchasing the manufacturer of transdermal patches . It was subsequently reported that a lawyer representing the firm did not disclose their ownership position in both companies. Asked about this on RTÉ Radio One yesterday, Sheridan explained that it was the only time that his firm had faced any trouble with US authorities and that, for Nutriband, it was seen as a minor issue and required the firm to correct submitted paperwork. Advertisement Unique selling point Sheridan has said he wants Nutriband to benefit those who are ill, developing patches that provide patients with a safe dose of medicines that are commonly abused – primarily opioids – targeting those who are in need of the controversial medicines. If abused, the drugs can cause long-term health complications, impact organ health and – in the case of synthetic and potent alternatives especially – minor doses can result in death. We're up and running! Excited to have announced my intention to seek a nomination for the upcoming Presidential election. I look forward to setting out my values and vision for the Presidency over the coming days and continuing to engage with Councillors across the country. — Gareth Sheridan (@GPSheridan1) August 11, 2025 Sheridan's business case is that there are still many people, in the US particularly, who need these pain medicines for proper health-related reasons. He believes the managed doses from his firm's patches is a unique selling point and a prevention of abuse and addiction. He said that there's been an increase of American patients being told to use over-the-counter pain medication for illnesses, and claims his patches could be a safer and more appropriate option. Pharmaceutical patches Sheridan in April said acquisitions and mergers were 'the strategy' for the company. Some of the previous owners from the purchased companies went on to join Sheridan and held positions at Nutriband for a short time. He explained, due to his own lack of expertise in pharmacology, he needed those who could help actually develop his ideas. He added: 'It also kept us away from expensive money. I am able to retain today a good proportion of the company because we didn't do angel [investor] rounds, seed rounds. We didn't do the traditional route.' News reports of the company's activities recently have focused on its newest patch, which would deliver a proper prescribed dose of fentanyl . The firm is still in ongoing discussions with the US's drugs regulator, the Food and Drug Administration. In preparation for its approval, it has offered shareholders particular stock options to raise funds. Success? Nutriband is yet to generate any revenue. In its most-recent public quarterly report, at the end of October last year, it recorded a net-loss of $1.3m. Speaking to The Entrepreneur Experiment in April, Sheridan said: 'In most public companies it's either one person makes a million dollars or, years later, dozens of people make multiple millions of dollars. So there's patience and trust involved.' The Áras hopeful, who has stepped back as CEO from Nutriband to pursuit the election later this year, said he is certain the company will be worth a billion dollars in the future. Sheridan said the firm has been careful not to waste any funding too: 'We've been very careful not to raise money that we don't need – money that is sitting in a bank account at the expense of shareholders [...] It's just little things like that.' He told RTÉ Radio One yesterday that he believes Nutriband will still achieve that goal, with or without him. He said that he intends to have a stake in the firm, should he be placed on the ballot and elected President. Sheridan said he is seeking to be nominated as a candidate to represent the interests of young people who feel that they must emigrate for work and other opportunities due to the housing situation here. He is due to announced his platform's values later this week. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Irish Daily Mirror
2 hours ago
- Irish Daily Mirror
Crystal Palace slams UEFA ruling with brutal response to Premier League rivals
Crystal Palace have declared that "sporting merit is meaningless" following the Court of Arbitration for Sport's decision to uphold UEFA's verdict demoting them from the Europa League after their FA Cup triumph. The Eagles' Wembley success in May had secured their place in the European tournament, but UEFA ruled they had violated multi-club ownership regulations and relegated them to the Europa Conference League. American tycoon John Textor held a 43 per cent stake in the south London club until offloading it in July, whilst also being the majority shareholder of Lyon, who have similarly qualified for the Europa League. Premier League rivals Nottingham Forest are set to replace them in Uefa's second continental competition - which has been another bone of contention. The Premier League side attempted to appeal as CAS but they have stuck by the ruling given by the governing body of European football and the Eagles have not hid their frustration in their latest statement claiming that "certain clubs, organisations and individuals have a unique privilege and power." The club said: "At a time when we should be celebrating our victory in the Community Shield at Wembley, the decision by UEFA and followed by the Court of Arbitration for Sport shows that sporting merit is rendered meaningless. "When we won the FA Cup against Manchester City on that momentous day in May, our manager and players earned the right to play Europa League football. We have been denied that opportunity. It appears that certain clubs, organisations and individuals have a unique privilege and power. "This growing and unhealthy influence has shattered the hopes and dreams of Crystal Palace supporters, and does not bode well for aspirational teams all over Europe competing to progress when rules and sanctions are unevenly applied in the most flagrant way. "Multi-club structures hide behind the charade of a "blind trust" while clubs such as ours, who have no connection to another club whatsoever, are prevented from playing in the same competition. To compound the injustice, clubs that appear to have huge informal arrangements with each other are also allowed to participate and even possibly play against each other. "While we respect the CAS tribunal members, the process is designed to severely restrict and, in our case, make it almost impossible to receive a fair hearing. Crystal Palace will play for the Community Shield as a result of winning the FA Cup (Image: PA) "The denial of all disclosure requests to obtain correspondence between the relevant parties, the refusal to allow witness testimony from those involved, and the general lack of formality and respect for law mean decisions cannot be properly challenged, leading to pre-determined outcomes. "UEFA's decision has wider implications for the governance of the sport. A combination of poorly conceived regulations and their unequal application means our brilliant fans will be deprived of the chance to watch this team compete in the Europa League for the first time in our history. This should be a turning point for football. "UEFA must fulfil its mandate to pass coherent rules which are properly communicated and applied, with reasonable cure periods to resolve uncertainty and consistent sanctions, treating all clubs equally with a proper appeal process. The European Court of Justice has made it clear that rulings similar to this will be under greater scrutiny from national courts in future. Only then will fairness and due process be granted to every team. "Although we continue to take legal advice on the next steps, we will compete in the Conference League with the same determination and will to win that characterises this incredible club."
